Sabine Irtan

90 statements · 3 topics · summaries given as host listed separately

Featured statements

▶ Ep 3 · 4:40

Radiological detected postoperative tumor residues impact outcomes only if active disease was demonstrated through post-operative MIBG scanning, which could have an impact on future radiotherapy strategies.

quote · High-risk Neuroblastoma

▶ Ep 3 · 2:58

We showed no impact of the radiological postoperative residue on EFS and OS. But we had an impact on the MIBG positive residue on EFS and OS with a difference of more than 20% of survival.

quote · High-risk Neuroblastoma

▶ Ep 19 · 0:40

Patients with er neuroblastoma need a heavy burden of treatment associating chemotherapy, immunotherapy, radiotherapy, and surgery to be cured.

quote · Neuroblastoma

▶ Ep 19 · 4:04

The difference between patients with MIBG-positive residue and patients with no residue or no MIBG-positive residue was still present for patients with partial or minimal response with a 10% survival difference.

clinical · Neuroblastoma

▶ Ep 557 · 4:40

Radiologically detected postoperative tumor residues impact outcomes only if active disease was demonstrated through post-operative MIBG scanning, which could have an impact on future radiotherapy strategies.

clinical · Pediatric Oncology

▶ Ep 557 · 3:20

Patients who had an MIBG-positive residue had 25% and 27% five-year event-free survival, whereas patients with no residue or no MIBG-positive residue had 51% five-year event-free survival.

clinical · Pediatric Oncology

Nothing matches these filters — clear the search or widen the filters.

Sabine's statements about High-risk Neuroblastoma 36 statements

Open the High-risk Neuroblastoma collection →

Dr. Sabine Irtan - Best of the Best in Pediatric Surgery 2025

▶ Ep 3 · 0:40

quote Patients with er neuroblastoma need a heavy burden of treatment associating chemotherapy, immunotherapy, radiotherapy, and surgery to be cured. ↗

▶ Ep 3 · 0:40

clinical Patients with high-risk neuroblastoma require chemotherapy, immunotherapy, radiotherapy, and surgery to be cured. ↗

▶ Ep 3 · 0:48

quote The role of surgery in this context remains controversial. ↗

▶ Ep 3 · 0:48

opinion The role of surgery in high-risk neuroblastoma remains controversial. ↗

▶ Ep 3 · 0:52

clinical Kewarm's 2020 JCO paper stated that complete macroscopic excision of the primary tumor improved both overall and event-free survival in 1,531 patients with stage 4 neuroblastoma. ↗

▶ Ep 3 · 1:08

clinical Kewarm's study based success of intervention and judgment on post-operative residue on the operative report, with no systematic radiological assessment. ↗

▶ Ep 3 · 1:14

quote No systematic radiological assessment of residue has been performed so far. ↗

▶ Ep 3 · 1:48

epidemiological The study included 283 patients (108 females, 175 males) diagnosed at a median age of 35 months. ↗

▶ Ep 3 · 1:57

epidemiological The primary tumor site was the abdomen in 95% of patients. ↗

▶ Ep 3 · 2:02

epidemiological The tumor origin was the adrenal gland in 81% of patients. ↗

▶ Ep 3 · 2:06

clinical Post-operative imaging was performed at a median of 62 days after surgery and was mainly CT scan or MRI. ↗

▶ Ep 3 · 2:17

epidemiological Residue was present in half of the patients. ↗

▶ Ep 3 · 2:20

epidemiological The median volume of the residue was 0.27 mL. ↗

▶ Ep 3 · 2:25

clinical In 28 patients the residue was a microcalcification. ↗

▶ Ep 3 · 2:29

epidemiological Only 11% of patients had a residue of more than 5 mL. ↗

▶ Ep 3 · 2:29

epidemiological Excluding patients with microcalcifications, the median residue volume was 1.04 mL. ↗

▶ Ep 3 · 2:40

epidemiological MIBG positivity of the residue was present in 70.5% of patients with a post-operative MIBG available. ↗

▶ Ep 3 · 2:40

epidemiological The residue was linked to the presence of IDRF in 71% of patients. ↗

▶ Ep 3 · 2:58

clinical Radiological post-operative residue showed no impact on event-free survival and overall survival. ↗

▶ Ep 3 · 2:58

quote We showed no impact of the radiological postoperative residue on EFS and OS. But we had an impact on the MIBG positive residue on EFS and OS with a difference of more than 20% of survival. ↗

▶ Ep 3 · 3:08

clinical MIBG-positive residue had an impact on event-free survival and overall survival with a difference of more than 20% of survival. ↗

▶ Ep 3 · 3:20

epidemiological Patients with no residue or no MIBG-positive residue had 51% five-year event-free survival. ↗

▶ Ep 3 · 3:20

clinical The survival difference between MIBG-positive and MIBG-negative residue groups was confirmed for five-year overall survival. ↗

▶ Ep 3 · 3:20

epidemiological Patients with MIBG-positive residue had 25% and 27% five-year event-free survival. ↗

▶ Ep 3 · 3:45

clinical External validation on the entire high-risk neuroblastoma cohort in patients with stage 4 neuroblastoma who had surgery and post-surgical MIBG evaluation confirmed the results. ↗

▶ Ep 3 · 4:04

clinical The survival difference between MIBG-positive residue and no/MIBG-negative residue was present even for patients with partial or minimal metastatic response, with a 10% survival difference. ↗

▶ Ep 3 · 4:26

epidemiological Half of patients operated on in expert centers have a tumor residue objectively identified on post-operative images of less than 1 mL. ↗

▶ Ep 3 · 4:36

epidemiological The residue was MIBG-positive in around 20% of patients. ↗

▶ Ep 3 · 4:40

quote Radiological detected postoperative tumor residues impact outcomes only if active disease was demonstrated through post-operative MIBG scanning, which could have an impact on future radiotherapy strategies. ↗

▶ Ep 3 · 4:40

clinical Radiologically detected post-operative tumor residues impact outcomes only if active disease was demonstrated through post-operative MIBG scanning. ↗

▶ Ep 3 · 4:54

quote We confirmed that complete resection should be maintained as a major surgical goal. However, metastatic response is an important prognostic cofactor. ↗

▶ Ep 3 · 4:54

guideline Complete resection should be maintained as a major surgical goal. ↗

▶ Ep 3 · 4:59

clinical Metastatic response is an important prognostic cofactor. ↗

▶ Ep 3 · 5:43

clinical For patients where the surgeon reported leaving nothing, almost half had residue on post-operative images. ↗

▶ Ep 3 · 5:57

clinical For patients where the surgeon reported leaving residue, imaging found residue in two-thirds and no residue in one-third. ↗

▶ Ep 3 · 5:57

quote Between what the surgeon said and what the radiologist says, there's a discrepancy that uh can impact also uh the, the question of should we let a residue or not. ↗

Sabine's statements about Neuroblastoma 27 statements

Open the Neuroblastoma collection →

Dr. Sabine Irtan - Best of the Best in Pediatric Surgery 2025

▶ Ep 19 · 0:40

quote Patients with er neuroblastoma need a heavy burden of treatment associating chemotherapy, immunotherapy, radiotherapy, and surgery to be cured. ↗

▶ Ep 19 · 0:40

clinical Patients with high-risk neuroblastoma need a heavy burden of treatment associating chemotherapy, immunotherapy, radiotherapy, and surgery to be cured. ↗

▶ Ep 19 · 0:48

quote The role of surgery in this context remains controversial. ↗

▶ Ep 19 · 0:48

opinion The role of surgery in high-risk neuroblastoma remains controversial. ↗

▶ Ep 19 · 1:48

epidemiological The study included 283 patients (108 females, 175 males) who had a diagnosis at a median age of 35 months. ↗

▶ Ep 19 · 1:57

epidemiological The primary tumor site was the abdomen in 95% of patients. ↗

▶ Ep 19 · 2:02

epidemiological The tumor origin was the adrenal gland in 81% of patients. ↗

▶ Ep 19 · 2:06

clinical The postoperative imaging was performed at a median of 62 days after surgery and was mainly a CT scan or MRI. ↗

▶ Ep 19 · 2:17

epidemiological Residue was present in half of the patients on post-operative imaging. ↗

▶ Ep 19 · 2:20

epidemiological The median volume of the residue was 0.27 mL. ↗

▶ Ep 19 · 2:25

epidemiological The residue was a microcalcification in 28 patients. ↗

▶ Ep 19 · 2:29

epidemiological Excluding patients with microcalcifications, the median residue volume was 1.04 mL, and only 11% of patients had a residue of more than 5 mL. ↗

▶ Ep 19 · 2:40

epidemiological The residue was linked to the presence of IDRF in 71% of patients. ↗

▶ Ep 19 · 2:40

epidemiological MIBG positivity of the residue was present in 70.5% of patients with a post-operative MIBG available. ↗

▶ Ep 19 · 2:58

clinical There was no impact of the radiological postoperative residue on event-free survival and overall survival. ↗

▶ Ep 19 · 3:08

clinical MIBG-positive residue had an impact on event-free survival and overall survival with a difference of more than 20% of survival. ↗

▶ Ep 19 · 3:20

clinical Patients who had an MIBG-positive residue had 25% and 27% five-year event-free survival, whereas patients with no residue or no MIBG-positive residue had 51% five-year event-free survival. ↗

▶ Ep 19 · 3:45

clinical External validation on the entire high-risk neuroblastoma cohort in patients with stage 4 neuroblastoma who had surgery and post-surgical MIBG evaluation confirmed the results, especially in patients with complete response of the metastasis. ↗

▶ Ep 19 · 4:04

clinical The difference between patients with MIBG-positive residue and patients with no residue or no MIBG-positive residue was still present for patients with partial or minimal response with a 10% survival difference. ↗

▶ Ep 19 · 4:26

clinical Half of the patients operated on in expert centers have a tumor residue objectively identified on postoperative images of less than 1 mL. ↗

▶ Ep 19 · 4:36

epidemiological The residue was MIBG-positive in around 20% of patients. ↗

▶ Ep 19 · 4:40

clinical Radiologically detected postoperative tumor residues impact outcomes only if active disease was demonstrated through post-operative MIBG scanning, which could have an impact on future radiotherapy strategies. ↗

▶ Ep 19 · 4:54

guideline Complete resection should be maintained as a major surgical goal. ↗

▶ Ep 19 · 4:59

clinical Metastatic response is an important prognostic cofactor in stage 4 neuroblastoma. ↗

▶ Ep 19 · 5:43

clinical For patients for whom the surgeon said they left nothing, almost half of the patients had still something on the postoperative images. ↗

▶ Ep 19 · 5:57

clinical For patients for whom the surgeon said they left something, residue was found in two-thirds of patients and no residue was found in one-third of patients. ↗

▶ Ep 19 · 5:57

quote I completely agree that Between what the surgeon said and what the radiologist says, there's a discrepancy that uh can impact also uh the, the question of should we let a residue or not. ↗

Sabine's statements about Pediatric Oncology 27 statements

Open the Pediatric Oncology collection →

Dr. Sabine Irtan - Best of the Best in Pediatric Surgery 2025

▶ Ep 557 · 0:40

clinical Patients with high-risk neuroblastoma need a heavy burden of treatment associating chemotherapy, immunotherapy, radiotherapy, and surgery to be cured. ↗

▶ Ep 557 · 0:40

quote Patients with er neuroblastoma need a heavy burden of treatment associating chemotherapy, immunotherapy, radiotherapy, and surgery to be cured. ↗

▶ Ep 557 · 0:48

quote The role of surgery in this context remains controversial. ↗

▶ Ep 557 · 0:48

opinion The role of surgery in high-risk neuroblastoma remains controversial. ↗

▶ Ep 557 · 1:48

epidemiological The study included 283 patients (108 females, 175 males) who had a diagnosis at a median age of 35 months. ↗

▶ Ep 557 · 1:57

epidemiological The primary tumor site was the abdomen in 95% of patients. ↗

▶ Ep 557 · 2:02

epidemiological The tumor origin was the adrenal gland in 81% of patients. ↗

▶ Ep 557 · 2:06

clinical The postoperative imaging was performed at a median of 62 days after surgery and was mainly a CT scan or MRI. ↗

▶ Ep 557 · 2:17

epidemiological Residue was present in half of the patients on post-operative imaging. ↗

▶ Ep 557 · 2:20

epidemiological The median volume of the residue was 0.27 mL. ↗

▶ Ep 557 · 2:25

epidemiological The residue was a microcalcification in 28 patients. ↗

▶ Ep 557 · 2:29

epidemiological Excluding patients with microcalcifications, the median residue volume was 1.04 mL, and only 11% of patients had a residue of more than 5 mL. ↗

▶ Ep 557 · 2:40

epidemiological MIBG positivity of the residue was present in 70.5% of patients with a post-operative MIBG available. ↗

▶ Ep 557 · 2:40

epidemiological The residue was linked to the presence of IDRF in 71% of patients. ↗

▶ Ep 557 · 2:58

clinical There was no impact of the radiological postoperative residue on event-free survival and overall survival. ↗

▶ Ep 557 · 3:08

clinical MIBG-positive residue had an impact on event-free survival and overall survival with a difference of more than 20% of survival. ↗

▶ Ep 557 · 3:20

▶ Ep 557 · 3:45

▶ Ep 557 · 4:04

▶ Ep 557 · 4:26

clinical Half of the patients operated on in expert centers have a tumor residue objectively identified on postoperative images of less than 1 mL. ↗

▶ Ep 557 · 4:36

epidemiological The residue was MIBG-positive in around 20% of patients. ↗

▶ Ep 557 · 4:40

▶ Ep 557 · 4:54

guideline Complete resection should be maintained as a major surgical goal. ↗

▶ Ep 557 · 4:59

clinical Metastatic response is an important prognostic cofactor in stage 4 neuroblastoma. ↗

▶ Ep 557 · 5:43

clinical For patients for whom the surgeon said they left nothing, almost half of the patients had still something on the postoperative images. ↗

▶ Ep 557 · 5:57

clinical For patients for whom the surgeon said they left something, residue was found in two-thirds of patients and no residue was found in one-third of patients. ↗

▶ Ep 557 · 5:57

quote I completely agree that Between what the surgeon said and what the radiologist says, there's a discrepancy that uh can impact also uh the, the question of should we let a residue or not. ↗

Summaries Sabine gave as host · 4 summaries

Recaps of other experts' statements, not Sabine's own clinical position.

Summaries Sabine gave as host · Neuroblastoma 2 summaries

Open the Neuroblastoma collection →

Dr. Sabine Irtan - Best of the Best in Pediatric Surgery 2025

▶ Ep 19 · 0:52

host summary Sabine Irtan summarizing the discussion: Kewarm stated in a 2020 GCO paper that complete macroscopic excision of the primary tumor improved both overall and event-free survival in a cohort of 1,531 patients with stage 4 neuroblastoma. ↗

▶ Ep 19 · 1:08

host summary Sabine Irtan summarizing the discussion: In Kewarm's study, the success of the intervention and judgment on the post-operative residue was based on the operative report with no systematic radiological assessment of residue performed. ↗

Summaries Sabine gave as host · Pediatric Oncology 2 summaries

Open the Pediatric Oncology collection →

Dr. Sabine Irtan - Best of the Best in Pediatric Surgery 2025

▶ Ep 557 · 0:52

▶ Ep 557 · 1:08